Skip to main content

Table 1 Descriptive baseline characteristics of patients with IgAN compared to matched general population reference individuals, siblings and spouses

From: Immunoglobulin A nephropathy and ischemic heart disease: a nationwide population-based cohort study

 

Main analysis

Sibling analysis

Spousal analysis

IgAN

General population reference

IgAN

Siblings

IgAN

Spouses

 

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Total

3945

19,272

3039

6729

2377

2377

Person-years (py)

55,527

287,677

44,796

105,096

35,484 (0)

38,893 (0)

Sex

 Female

1172 (29.7%)

5780 (30.0%)

869 (28.6%)

3307 (49.1%)

690 (29.0%)

1710 (71.9%)

 Male

2773 (70.3%)

13,492 70.0%)

2170 (71.4%)

3422 (50.9%)

1687 (71.0%)

667 (28.1%)

Age

 Age, mean (SD)

39.4 (16.5)

38.9 (16.2)

35.9 (14.9)

35.3 (16.6)

43.5 (14.3)

42.9 (14.6)

 Age, median (IQR)

38.9 (26.5, 51.3)

38.3 (26.2, 50.5)

35.3 (23.9, 47)

35.7 (23, 47.9)

43.1 (32.7, 53.9)

42.8 (32.3, 53.2)

  ≤ 17 years

380 (9.6%)

1894 (9.8%)

361 (11.9%)

1093 (16.2%)

64 (2.7%)

91 (3.8%)

 18–39 years

1706 (43.2%)

8541 (44.3%)

1485 (48.9%)

2872 (42.7%)

943 (39.7%)

947 (39.8%)

 40–59 years

1390 (35.2%)

6778 (35.2%)

1015 (33.4%)

2312 (34.4%)

1046 (44.0%)

1036 (43.6%)

  ≥ 60 years

469 (11.9%)

2059 (10.7%)

178 (5.9%)

452 (6.7%)

324 (13.6%)

296 (12.5%)

 Unknown

    

0 (0.0%)

7 (0.3%)

Year of inclusion

 Entry year, median (IQR)

2001 (1994, 2007)

2001 (1994, 2007)

2002 (1994, 2008)

2001 (1994, 2007)

2000 (1993, 2006)

2000 (1993, 2006)

 1974–1988

438 (11.1%)

2168 (11.2%)

317 (10.4%)

728 (10.8%)

326 (13.7%)

326 (13.7%)

 1989–2001

1565 (39.7%)

7662 (39.8%)

1187 (39.1%)

2670 (39.7%)

1024 (43.1%)

1024 (43.1%)

 2002–2015

1942 (49.2%)

9442 (49.0%)

1535 (50.5%)

3331 (49.5%)

1027 (43.2%)

1027 (43.2%)

Follow up time

 Mean (SD)

14.1 (8.47)

14.9 (8.52)

14.7 (8.49)

15.6 (8.51)

14.9 (8.76)

16.4 (8.67)

 Median (IQR)

12.7 (7.45, 19.6)

13.7 (8.11, 20.7)

13.5 (7.99, 20.4)

14.5 (8.61, 21.5)

13.8 (8.01, 20.7)

15.5 (9.3, 22.5)

 0–1 years

79 (2.0%)

194 (1.0%)

35 (1.2%)

41 (0.6%)

56 (2.4%)

20 (0.8%)

 1–4 years

464 (11.8%)

2001 (10.4%)

314 (10.3%)

569 (8.5%)

248 (10.4%)

176 (7.4%)

  ≥ 5 years

3402 (86.2%)

17,077 88.6%)

2690 (88.5%)

6119 (90.9%)

2073 (87.2%)

2181 (91.8%)

Reason for end of follow up

 May 31, 2017

3022 (76.6%)

16,000 83.0%)

2524 (83.1%)

6020 (89.5%)

1759 (74.0%)

2021 (85.0%)

 Emigration

105 (2.7%)

727 (3.8%)

80 (2.6%)

160 (2.4%)

48 (2.0%)

45 (1.9%)

 IHD (death or diagnosis)

371 (9.4%)

1070 (5.6%)

206 (6.8%)

242 (3.6%)

290 (12.2%)

126 (5.3%)

 Death from other cause

447 (11.3%)

1475 (7.7%)

229 (7.5%)

307 (4.6%)

280 (11.8%)

185 (7.8%)

Country of birth

 Nordic

3602 (91.3%)

17,322 89.9%)

2971 (97.8%)

6568 (97.6%)

2128 (89.5%)

2085 (87.7%)

 Non-Nordic

342 (8.7%)

1948 (10.1%)

68 (2.2%)

161 (2.4%)

249 (10.5%)

229 (9.6%)

 Unknown

1 (< 1%)

2 (< 1%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

63 (2.7%)

Level of education

 Compulsory school (0–9 years)

817 (20.7%)

3852 (20.0%)

506 (16.7%)

1195 (17.8%)

527 (22.2%)

435 (18.3%)

 Upper sec. School (10–12 years)

1759 (44.6%)

8690 (45.1%)

1415 (46.6%)

3205 (47.6%)

1007 (42.4%)

1044 (43.9%)

 University (>  12 years)

1276 (32.3%)

6279 (32.6%)

1066 (35.1%)

2090 (31.1%)

816 (34.3%)

817 (34.4%)

 Unknown

93 (2.4%)

451 (2.3%)

52 (1.7%)

239 (3.6%)

27 (1.1%)

81 (3.4%)

Comorbititya

 HSP/IgAVb

236 (6.0%)

30 (0.2%)

203 (6.7%)

22 (0.3%)

94 (4.0%)

5 (0.2%)

 Diabetes, type 1 or 2

170 (4.3%)

309 (1.6%)

97 (3.2%)

107 (1.6%)

101 (4.2%)

45 (1.9%)

 Other systemic inflammatory disease

313 (7.9%)

459 (2.4%)

224 (7.4%)

207 (3.1%)

193 (8.1%)

77 (3.2%)

 Hypertension

1241 (31.5%)

344 (1.8%)

891 (29.3%)

139 (2.1%)

809 (34.0%)

51 (2.1%)

 Heredity for IgAN

38 (1.0%)

28 (0.1%)

    

 Heredity for ESRD

84 (2.1%)

139 (0.7%)

    
  1. Continuous parameters are presented as mean values with standard deviations. Categorical values are presented as numbers and percentages. For all definitions, see main text or Additional file 1
  2. aBefore study inclusion date (biopsy date in IgAN patients and corresponding date in reference individuals)
  3. bHSP/IgAV Henoch-Schönlein’s purpura, or systemic IgA vasculitis